VENTURE (12+ years), TRAVERSE OLE (12+ years)
86% of patients reduced or eliminated their OCS dose at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) (ITT population, VENTURE).13
A 70% significant reduction in OCS dose (median 100%) from baseline was observed at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint).1
In addition, 79% of patients from VENTURE eliminated their OCS dose at Week 96 in the TRAVERSE OLE study (secondary endpoint).9
Results from TRAVERSE are descriptive. There are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.
dOCS reduction was at investigators’ discretion.9